Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. (Q53299129)

13 May 2018

title

Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. (English)

1 reference

13 May 2018

author

Johannes Kornhuber

10

1 reference

13 May 2018

Jens Wiltfang

11

1 reference

13 May 2018

Claudia Trenkwalder

8

Claudia Trenkwalder

1 reference

13 May 2018

4

Brit Mollenhauer

1 reference

13 May 2018

3

Piotr Lewczuk

1 reference

13 May 2018

Hermann Esselmann

5

Hermann Esselmann

1 reference

13 May 2018

Mirko Bibl

12

Mirko Bibl

1 reference

13 May 2018

Volker Welge

1

Volker Welge

1 reference

13 May 2018

Hans-Wolfgang Klafki

6

Hans-Wolfgang Klafki

1 reference

13 May 2018

author name string

Oliver Fiege

2

1 reference

13 May 2018

Stefanie Wolf

7

1 reference

13 May 2018

Markus Otto

9

1 reference

13 May 2018

publication date

14 January 2009

1 reference

13 May 2018

Journal of Neural Transmission

published in

1 reference

13 May 2018

volume

116

1 reference

13 May 2018

page(s)

203-212

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s00702-008-0177-6

exact match

0 references

cites work

Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0177-6

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0177-6

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0177-6

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0177-6

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-008-0177-6

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

21 January 2018

1 reference

12 December 2020

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

1 reference

12 December 2020

Progressive supranuclear palsy and corticobasal degeneration.

1 reference

12 December 2020

Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.

1 reference

12 December 2020

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

1 reference

12 December 2020

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

12 December 2020

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

1 reference

12 December 2020

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

12 December 2020

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

12 December 2020

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

1 reference

12 December 2020

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

1 reference

12 December 2020

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

1 reference

12 December 2020

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

12 December 2020

Taps to Alzheimer's patients: a continuous Japanese study of cerebrospinal fluid biomarkers.

1 reference

12 December 2020

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

1 reference

12 December 2020

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

1 reference

12 December 2020

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

The levels of cerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently.

1 reference

12 December 2020

Clinical guidelines for idiopathic normal pressure hydrocephalus

1 reference

12 December 2020

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

12 December 2020

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

1 reference

12 December 2020

1 reference

12 December 2020

CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

1 reference

12 December 2020

Increased cerebrospinal fluid A beta38/A beta42 ratio in Alzheimer disease

1 reference

12 December 2020

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

12 December 2020

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

1 reference

12 December 2020

Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review

1 reference

12 December 2020

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

1 reference

12 December 2020

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

1 reference

12 December 2020

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

1 reference

12 December 2020

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

1 reference

12 December 2020

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.

1 reference

12 December 2020

Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.

1 reference

12 December 2020

10.1007/S00702-008-0177-6

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

19142572

1 reference

13 May 2018